modern insulin analogues are a convenient new approach or tool to glycaemic control , associated with low number of hypoglycaemia and favourable weight change . a1chieve , a multinational , 24-week , non - interventional study , assessed the safety and effectiveness of insulin analogues in people with t2 dm ( n = 66,726 ) in routine clinical care . please refer to editorial titled : the a1chieve study : mapping the ibn battuta trail . the patient characteristics for the entire cohort divided as insulin - nave and insulin users is shown in the table 1 . the majority of patients ( 38.6% ) started on or were switched to insulin detemir . other groups were biphasic insulin aspart ( n = 47 ) , insulin aspart ( n = 1 ) , basal insulin plus insulin aspart ( n = 35 ) and other insulin combinations ( n = 6 ) . overall demographic data after 24 weeks of treatment , overall hypoglycaemic events or episodes reduced from 23.6 events / patient - year to 15.7 events / patient - year in insulin user group whereas hypoglycaemia increased from 2.3 events / patient - year to 3.1 events / patient - year in the insulin nave group . however , this hypoglycaemia incidence in insulin naive group at 24 weeks was still lower than that observed in insulin users at baseline . blood pressure decreased and lipid profile improved in the total cohort , but the findings were limited by number of observations . all parameters of glycaemic control improved from baseline to study end in the total cohort [ table 4 ] . overall efficacy data of the total cohort , 47 patients started on biphasic insulin aspart  ogld , of which 33 ( 70.2% ) were insulin nave and 14 ( 29.8% ) were insulin users . after 24 weeks of treatment , hypoglycaemic events reduced from 30.6 events / patient - year to 22.3 events / patient - year in insulin users while hypoglycaemia increased from 0.0 events / patient - year to 0.8 events / patient - year in insulin nave group . biphasic insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin nave and insulin user groups [ table 7 ] . biphasic insulin aspartoral glucose - lowering drug efficacy data of the total cohort , 35 patients started on basal + insulin aspart  ogld , of which 10 ( 28.6% ) were insulin nave and 25 ( 71.4% ) were insulin users . after 24 weeks of treatment , hypoglycaemic events reduced for both insulin nave and insulin user groups ( insulin nave : from 13.0 events / patient - year to 8.7 events / patient - year , insulin user : from 25.0 events / patient - year to 17.1 events / patient - year ) . basal+insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were basal + insulin aspart  oglds for both insulin nave and insulin user groups [ table 10 ] . basal+insulin aspartoral glucose - lowering drug efficacy data of the total cohort , 56 patients started on insulin detemir  ogld , of which 44 ( 78.6% ) were insulin nave and 12 ( 21.4% ) were insulin users . after 24 weeks of starting or switching to insulin detemir , hypoglycaemic events reduced from 14.1 events / patient - year to 6.5 events / patient - year in insulin users while hypoglycaemia increased from 1.8 events / patient - year to 4.0 events / patient - year in insulin nave group . insulin detemiroral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir  oglds for both insulin - nave and insulin user groups [ table 13 ] . insulin detemiroral glucose - lowering drug efficacy data of the total cohort , only 1 patient started on or switched to insulin aspart  ogld and was insulin user . of the total cohort , 47 patients started on biphasic insulin aspart  ogld , of which 33 ( 70.2% ) were insulin nave and 14 ( 29.8% ) were insulin users . after 24 weeks of treatment , hypoglycaemic events reduced from 30.6 events / patient - year to 22.3 events / patient - year in insulin users while hypoglycaemia increased from 0.0 events / patient - year to 0.8 events / patient - year in insulin nave group . biphasic insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin nave and insulin user groups [ table 7 ] . of the total cohort , 35 patients started on basal + insulin aspart  ogld , of which 10 ( 28.6% ) were insulin nave and 25 ( 71.4% ) were insulin users . after 24 weeks of treatment , hypoglycaemic events reduced for both insulin nave and insulin user groups ( insulin nave : from 13.0 events / patient - year to 8.7 events / patient - year , insulin user : from 25.0 events / patient - year to 17.1 events / patient - year ) . basal+insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were basal + insulin aspart  oglds for both insulin nave and insulin user groups [ table 10 ] . of the total cohort , 56 patients started on insulin detemir  ogld , of which 44 ( 78.6% ) were insulin nave and 12 ( 21.4% ) were insulin users . after 24 weeks of starting or switching to insulin detemir , hypoglycaemic events reduced from 14.1 events / patient - year to 6.5 events / patient - year in insulin users while hypoglycaemia increased from 1.8 events / patient - year to 4.0 events / patient - year in insulin nave group insulin detemiroral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir  oglds for both insulin - nave and insulin user groups [ table 13 ] . of the total cohort , only 1 patient started on or switched to insulin aspart  ogld and was insulin user . our study reports improved glycaemic control following 24 weeks of treatment with any of the insulin analogues ( biphasic insulin aspart ; basal + insulin aspart ; insulin detemir ; insulin aspart ) with or without ogld . though the findings are limited by number of patients , still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in saiss , morocco .
background : the a1chieve , a multicentric ( 28 countries ) , 24-week , non - interventional study evaluated the safety and effectiveness of insulin detemir , biphasic insulin aspart and insulin aspart in people with t2 dm ( n = 66 726 ) in routine clinical care across four continents.materials and methods : data was collected at baseline , at 12 weeks and at 24 weeks . this short communication presents the results for patients enrolled from saiss , morocco.results:a total of 145 patients were enrolled in the study . 
 four different insulin analogue regimens were used in the study . 
 study patients had started on or were switched to biphasic insulin aspart ( n = 47 ) , insulin detemir ( n = 56 ) , insulin aspart ( n = 1 ) , basal insulin plus insulin aspart ( n = 35 ) and other insulin combinations ( n = 6 ) . at baseline 
 glycaemic control was poor for both insulin nave ( mean hba1c : 10.4% ) and insulin user ( mean hba1c : 9.8% ) groups . 
 after 24 weeks of treatment , both the study groups showed improvement in hba1c ( insulin nave : 2.7% , insulin users : 2.5% ) . 
 sadrs including major hypoglycaemia did not occur in any of the study patients.conclusion:starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia .